FAQs

How much does IV Therapy cost?

Costs can fluctuate widely depending on your treatment goals. A single IV Infusion session is between $149-$279. Additional costs may include diagnostic testing, doctor consultations, supplements, and health coaching.

How soon will I start to see results?

Results will begin to show fairly quickly! Most guests experience mild improvements at the beginning, and those benefits continue to increase with subsequent visits. Depending on your prescribed IV Infusion treatment plan, there may be a “build-up” stage early on to get your body prepared for the full dose of vitamins.

How many IV treatments will I need?

It all depends on your therapeutic goals. Your Fuse IV physician will create a custom treatment plan for you based on the specific condition you are working on. However, the ReFuel Infusion is available as a stand alone treatment as any time if you need a quick boost of hydration and electrolytes!

Are results guaranteed?

While we would love to provide an absolute, we simply can’t guarantee results because everyone’s body processes things differently. Either way, we assure you that we will do everything in our power to help you get the treatments you need to feel better.

Is this covered by my insurance?

Fuse IV services are not covered by insurance. Read our Office Policies to learn more.

Research

Nutritional IV Therapy is a heavily researched area, particularly for High Dose Vitamin C. For a brief rundown of the results we recommend visiting Cancer.gov‘s page on the topic.

Below is a list of the numerous studies that have been published in the area of Nutritional IV Therapy. We will continue to update this list as more research is published!

High Dose Vitamin C IV Therapy

  1. Kurbacher C, Wagner U, Kolster B, Andreoo P, Krebs D, Bruckner H. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer LeY 1996;103:183–9.
  2. Reddy V, Khanna N, Singh N, Vitamin. C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilizing P53. Biochem Biophys Res Commun 2001;282:409–15.
  3. Abdel-LaJff MM et al. Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. J Chemother 2005; 17:5:539-49 vitamin C enhances the antitumor activity of 5-Fu and cisplatin, in part by inhibiting translocation of NF-kappaB and AP-1, and sensitizes cancer cells to drug- induced cell death
  4. Reddy VG et al. Vitamin C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilizing p53. Biochem Biophys Res Commun 2001; 282:2:409-15 …… then sensitized HeLa cells to cell-cycle arrest, cell death/apoptosis induced by cisplatin, and etoposide
  5. Prasad KN, Hernandez C, Edwards-Prasad J, Nelson J, Borus T, Robinson WA. Modification of the effect of tamoxifen, cis-plaJn, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer. 1994;22(3):233-45. PMID: 7877893
  6. Sarna S et al. Chemo-immunotherapeutical studies on Dalton’s lymphoma mice using cisplatin and ascorbic acid: synergistic antitumor effect in vivo and in vitro. Arch Immunol Ther Exp (Warsz) 1993; 41:5-6:327-33
  7. Prasad SB et al. Use of subtherapeutical dose of cisplatin and Vitamin C against murine Dalton’s lymphoma. Pol J Pharmacol Pharm 1992; 44:4:383-91
  8.  Yam D et al. Suppression of tumor growth and metastasis by dietary fish oil combined with vitamins E and C and cisplatin. Cancer Chemother Pharmacol 2001; 47:1:34-40
  9. Weijl NI et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double- blind, placebo-controlled study. Eur J Cancer 2004;40:10:1713-23.
  10. Sullivan, G. et. al. (2011, November). Prospective Randomized Phase I/IIa Pilot Trial to Assess Safety and Benefit Administering High Dose Intravenous Ascorbate in Combination with Chemotherapy in Newly Diagnosed Advanced Stage III or Stage IV Ovarian Cancer. Moderated Abstract [6] presented at the Society for Integrative Oncology, Cleveland, OH.
  11. Ma, Y. Drisko, J. Poilreddy, K. (2011, November). Synergistic Effects of Ascorbate with Carboplatin against Human Ovarian Cancer in Vitro and in Vivo. Moderated Abstract [20] presented at the Society for Integrative Oncology, Cleveland, OH.
  12. Pathak A, Bhutani M, Guleria R, Bal S, Mohan A, MohanJ B, et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J Am Coll Nutr 2005;24:16–21.
  13. Fromberg, A, et.al. Ascorbate Exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol, 67:1157-1166, 2011. DOI 10.1007/s00280-010-1418-6 (Springer online).
  14. Prasad K, Sinha P, Ramanujam M, Sakamoto A. Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc Natl Acad Sci USA 1979;76:829–32.
  15. Nagy B et al. Chemosensitizing effect of Vitamin C in combination with 5-fluorouracil in vitro. In Vivo 2003; 17:3:289-92
  16. Abdel-LaJff MM et al. Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. J Chemother 2005; 17:5:539-49 vitamin C enhances the antitumor activity of 5-Fu and cisplatin, in part by inhibiting translocation of NF-kappaB and AP-1, and sensitizes cancer cells to drug-induced cell death
  17. 5-FU ASC with K3 Positive in vivo: Taper H, de Gerlache J, Lans M, Roberfroid M. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int J Cancer 1987;40:575–9.
  18. MonJ DA, et. al. Phase I evaluation of intravenous ascorbic Acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794. Epub 2012 Jan 17.
  19. Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, Chen Q. Pharmacologic ascorbate synergizes with gemcitabine in pre-clinical models of pancreatic cancer. Free Radic. Biol. Med. 2011; 51
  20. MarJnoo S, Ranzato E, Burlando B. In vitro screening of synergistic ascorbate- drug combinations for the treatment of malignant mesothelioma. Toxicol In Vitro. 2011 Dec;25(8):1568-74. Epub 2011 May 27. PMID:21645609
  21. Joseph J. Cullen, Douglas R. Spitz, and Garry R. BueYner . Comment on “Pharmacologic ascorbate synergizes with Gemcitabine in pre-clinical models of pancreatic cancer” i.e. All we are saying is, give C a chance. Free Radic Biol Med. 2011 June 15; 50(12): 1726–1727. doi:10.1016/j.freeradbiomed.2011.03.030.
  22. Ma, Y. et. al. (2011, November). Pharmacologic Ascorbate Synergizes with Gemcitabine in Pre-Clinical Models of Pancreatic Cancer. Moderated Abstract [19] presented at the Society for Integrative Oncology, Cleveland, OH.
  23. Martinoo S, Ranzato E, Burlando B. In vitro screening of synergistic ascorbate- drug combinations for the treatment of malignant mesothelioma. Toxicol In Vitro. 2011 Dec;25(8):1568-74. Epub 2011 May 27. PMID: 21645609
  24. Kassouf W, Highshaw R, Nelkin G, Dinney C, Kamat A, Vitamins C. K3 sensitize human urothelial tumors to gemcitabine. J Urol 2006;176:1642–7.
  25. Kurbacher C, Wagner U, Kolster B, Andreoo P, Krebs D, Bruckner H. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer LeY 1996;103:183–9.
  26. Pathak AK et al. Potentiation of the effect of paclitaxel and carboplatin by antioxidant mixture on human lung cancer h520 cells. J Am Coll Nutr. 2002 Oct;21:5:416-21.
  27. Pathak A, Bhutani M, Guleria R, Bal S, Mohan A, MohanJ B, et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J Am Coll Nutr 2005;24:16–21.
  28. D’Souza GG, Wang T, Rockwell K, Torchilin VP. Surface modification of pharmaceutical nanocarriers with ascorbate residues improves their tumor-cell association and killing and the cytotoxic action of encapsulated paclitaxel in vitro. Pharm Res. 2008 Nov; 25(11):2567-72. Epub 2008 Jul 11. PMID: 18618230
  29. Sawant RR, Vaze OS, Rockwell K, Torchilin VP. Palmitoyl ascorbate-modified liposomes as nanoparticle plavorm for ascorbate-mediated cytotoxicity and paclitaxel co-delivery. Eur J Pharm Biopharm. 2010 Aug;75(3):321-6. Epub 2010 Apr 28. PMID: 20433922
  30. Sawant RR, Vaze OS, Wang T, D’Souza GG, Rockwell K, Gada K, Khaw BA, Torchilin VP. Palmitoyl ascorbate liposomes and free ascorbic acid: comparison of anticancer therapeutic effects upon parenteral administration. Pharm Res. 2012 Feb;29(2): 375-83. Epub 2011 Aug 16. PMID: 21845505
  31. Sullivan, G. et. al. (2011, November). Prospective Randomized Phase I/IIa Pilot Trial to Assess Safety and Benefit Administering High Dose Intravenous Ascorbate in Combination with Chemotherapy in Newly Diagnosed Advanced Stage III or Stage IV Ovarian Cancer. Moderated Abstract [6] presented at the Society for Integrative Oncology, Cleveland, OH.